We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Omega Diagnostics Group Plc | ODX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.20 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.20 | 2.20 |
| Top Posts |
|---|
Posted at 31/8/2023 06:39 by terminator101 No company that has ever done a share consolidation has done well for existing investors. "Provides more options for the company in the future" tells you everything you need to know ;-) |
Posted at 21/3/2023 07:01 by xtrmntr The cash flow statement is the first thing I go to when looking at the financial statements.We're going to do a walkthrough on a company that was popular last year called Omega Diagnostics (ODX).What went wrong?This is a company that got caught up in the testing hype, then failed to deliver on its revenues.Some blame the government. Some blame the board.But regardless of who is to blame, the warning signs were clear in the cash flow statement.Cash flow statements show how cash moves through the business and can tell us if a company:may need to raise moneyconverts its profits into cashis spending hefty amounts on capexBy the end of this email, you'll know how to work your way around the three parts of the cash flow statement.Let's get started on the first part: the cash flow statement of operations. Operating cash flow statement (OCF)The operating cash flow statement shows if a business is self-sustaining in its ordinary course of business.It starts with the company's bottom line (net income/loss) and then works its way back to cash generated/used from operations by the company.To do this, the company adjusts items on its P&L.Let's look at ODX's cash flow statement.Source: SharePad (risk-free trial and free month worth £74 here)This company made a £2.7m loss in its half-year report.But it doesn't mean that it used £2.7m from its cash reserves.This is where the OCF comes in handy.For example, we can see straight away that the company adjusts for depreciation.Depreci |
Posted at 29/1/2023 13:41 by thirty fifty twenty hi misterxyes i agree completely. in particular i have researched the CFO's patterns and involvement with the other PLC's he has been involved with in the past and then too (twice) he has bought at prices before then selling the business to an outsider at much higher prices (12-18mths later). also they are both heavily incentivised with share options etc... so why spend real money when one is going to be rewarded anyway, unless it seems like an excellent risk/reward. the only negative scenario i could contemplate is that they are trying to inflate the price ... now they dont need to do that to raise funds (since they have c.5m net CASH in the bank) but it was for acquisitions? so i see that as a possibility (albeit outside) but one which i would be happy with as any acquisitions increase the size of the MV which brings in more investors which typically gives the overall company a higher rating. so, for me, all the scenerios seem positive. though the biggest sign overall is the fantastic chart which has obviously shaken the crash from the covid mania peaks and is now forming a very strong recovery pattern. All IMHO, DYOR + BoL ODX is in my top5 holdings |
Posted at 25/11/2022 14:58 by masurenguy Interesting write up on this company by Private Punter.Current shareholders shown below. I have no position here so far. Directors' Shareholdings Simon Douglas 760,001: 0.32% Jeremy Millard 1,025,000: 0.43% Jag Grewal 894,926: 0.38% Chris Lea 900,000: 0.38% Significant Shareholders Hargreaves Lansdown, stockbrokers (EO):52,534,721: 22.10% Interactive Investor (EO):32,999,294: 13.88% Spreadex Limited: 24,329,621: 10.24% HSDL, stockbrokers (EO): 22,578,265: 9.50% IG Markets, stockbrokers (EO):14,624,555: 6.15% Walker Crips Investment Management:13,511,79 AJ Bell, stockbrokers (EO):13,282,716: 5.59% Barclays Smart Investors (EO): 11,725,756: 4.93% Cantor Fitzgerald Europe:9,356,635: 3.94% HSBC DVB Account:8,010,574: 3.37% Shareholding information last updated as at 30 September 2022 The number of shares in issue is 237,685,180 The percentage of shares not in public hands at 30 June 2022 is 11.75%. (Shares not in public hands are defined as substantial shareholders of 10% or more plus shares held by directors).There are no shares held as treasury shares. |
Posted at 24/11/2022 08:54 by broken_arrow1 It is worth remembering that large buyers were paying up-to 4.5p a share yesterday, there were a number of auctions, this suggests institutional investors are acquiring.Early doors profit taking by retail traders will shortly dry up - it is evident the market does not want to let new buyers in cheaply. |
Posted at 16/11/2022 12:37 by mam fach Took several attempts to get my order filled.Reported as a Sell. Investors are definitely piling in. IMHO |
Posted at 14/3/2022 11:04 by sanks 11 MAR 2022Key points: Omega diagnostics shares plunged 21.9% today, leaving many puzzled. The decline was triggered by the HSA’s disapproval of its COVID-19 test. However, the company has pivoted to the COVID-19 self-test market. The company expressed its disappointment with the HSA’s ruling, which came about because of the insufficient data released by the company to the regulator. However, the company said it had switched its focus to the self-test market with significant growth potential and is working extremely hard to meet the 31 March 2022 deadline for submitting the data for its CE Mark application. The grant of a CE Mark for Omega’s COVID-19 self-test would allow the firm to market its drug across the European Union targeting a more extensive customer base than the UK market. Investors will be waiting anxiously to see if the firm can meet the 31 March deadline, which is just twenty days away. Jag Grewal, Omega Diagnostics CEO, commented: “Whilst this is clearly disappointing, our plans do not include any contribution from COVID-19 antigen tests, as we focus the business on driving growth in our Health & Nutrition division.” Luckily for investors, the company has other diagnostic tests for different diseases, including food sensitivity. For example, it tests for acute allergic reactions to over 200 foods using its Food Detective® point-of-care test and its FoodPrint® laboratory-based system. Omega also sells an advanced CD4 test that test for advanced forms of HIV, which is mainly sold in emerging market countries. However, the demand for such tests is not as high as for COVID-19 tests. It remains to be seen if Omega’s COVID-19 self-test shall gain CE Mark approval. |
Posted at 10/2/2022 12:41 by demark didn't ODX on 31/01/2022 say the fundraisewould be at a discount?! RNS- 31 jan 2022 Speculation regarding a potential fundraise Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products , notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising. Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price. Any fundraise would include an open offer to accommodate retail investors. As per the announcement of 19 January, the Company has significant cash resources . Accordingly, there is no immediate need to raise additional capital and the Company may choose not to proceed with a fundraising until such time as conditions are more favourable. A further announcement will be made in due course as necessary. |
Posted at 31/1/2022 13:44 by alfredotupper NXC (says he's ex-chairman David Evans) - 28 Nov 2021 - 22:25:37 - 11248 of 11907"I have been reflecting on the potential for upside from the current price ( which I believe is underpinned by the other two divisions)." So according to NXC the price at 28th November, about 26p, was underpinned by the other two divisions. Today we got "Omega...notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising. Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price. Any fundraise would include an open offer to accommodate retail investors." So the investors and shareholders they approached didn't even think 10p was underpinned by the other two divisions. Sometimes it seems NXC would struggle to tie his own shoe laces. If you feel you have been misled by directors I suggest you report it to FCA. |
Posted at 13/4/2021 06:23 by dafad avacta have an investor presentation on the 22nd April,lets hope ther is news before thenNotice of Results and Investor Presentation AVACTA GROUP PLC Released 07:00:05 13 April 2021 RNS Number : 2088V Avacta Group PLC 13 April 2021 13 April 2021 Avacta Group plc ("Avacta" or "the Group") Notice of Results and Investor Presentation Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, will announce its financial results for the 12 months ended 31 December 2020 on Thursday, 22 April 2021. Analyst briefing A sell-side analyst briefing given by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will be held by webcast presentation, followed by a Q&A session, at 9.30am BST on Thursday, 22 April 2021. Pre-registration is required for attendance to the call. To confirm attendance, please email Avacta@fticonsulting The presentation will be posted on the Company's website at the following address: hxxps://avacta.com/i Investor webinar An investor webinar presentation by Alastair Smith, Chief Executive Officer; Tony Gardiner, Chief Financial Officer; and Neil Bell, Chief Development Officer, will take place at 11:00am BST on Thursday, 22 April 2021. The webinar is open to all existing and potential investors and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and then click "Add to meet" Avacta Group via the following link to join the webinar: hxxps://www.investor Investors who already follow Avacta Group plc on the Investor Meet Company platform will automatically be invited. - Ends - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
